US Stock Insider Trading | GeneDx Holdings Discloses 3 Insider Transactions on February 2

K-LinePoet · 2026-02-04T00:09:20+00:00

On February 2, 2026, GeneDx Holdings disclosed multiple insider transactions. Director Stueland Katherine sold 1,653 shares on January 29. Additionally, executive Feeley Kevin conducted multiple stock sale transactions involving large quantities and significant total amounts. These transactions reflect market activities by the company's insiders.

K-LinePoet

2026-02-04 00:09:20

Abstract generation in progress

On February 2, 2026, GeneDx Holdings (WGS) disclosed three insider trading transactions. Director Stueland Katherine sold 1,653 shares on January 29, 2026.

【Recent Insider Transactions】

Disclosure Date	Position	Name	Transaction Date	Buy/Sell	Quantity	Price per Share/USD	Total Amount/USD
February 2, 2026	Director	Stueland Katherine	January 29, 2026	Sell	1653	94.00	$155,400
February 2, 2026	Executive	Feeley Kevin	January 29, 2026	Sell	2	92.06	$184.12
February 2, 2026	Executive	Feeley Kevin	January 29, 2026	Sell	315	94.00	$29,610
December 18, 2025	Executive	Feeley Kevin	December 16, 2025	Sell	215	142.12	$30,503.80
December 18, 2025	Executive	Feeley Kevin	December 16, 2025	Sell	127	140.45	$17,871.15
December 18, 2025	Executive	Feeley Kevin	December 16, 2025	Sell	951	141.20	$134,389.20
December 18, 2025	Executive	Feeley Kevin	December 16, 2025	Sell	131	138.93	$18,177.83
December 18, 2025	Executive	Feeley Kevin	December 16, 2025	Sell	334	144.27	$48,213.18
December 18, 2025	Executive	Feeley Kevin	December 16, 2025	Sell	366	140.08	$51,245.28
December 18, 2025	Executive	Feeley Kevin	December 16, 2025	Sell	578	145.36	$84,095.68

【Company Information】

GeneDx Holdings Corp. is a company incorporated in Delaware on July 10, 2020. Sema4 is a patient-centered health intelligence company dedicated to advancing healthcare through data-driven insights. Sema4 leverages artificial intelligence and machine learning applied to multidimensional, longitudinal clinical and genomic data to build dynamic models of human health and define optimal personalized health trajectories, transforming healthcare. Centrellis is their innovative health intelligence platform capable of providing a more comprehensive understanding of disease and health, offering scientifically driven solutions for the most urgent medical needs.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.